UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Swedish MS registry - clinical support tool and scientific resource

Acta neurologica Scandinavica, 2015-07, Vol.132 (S199), p.11-19

2015

Volltextzugriff (PDF)

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

JAMA neurology, 2020-02, Vol.77 (2), p.184

2020

Volltextzugriff (PDF)

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients

Annals of neurology, 2020-05, Vol.87 (5), p.688-699

2020

Volltextzugriff (PDF)

Effect of Smoking Cessation on Multiple Sclerosis Prognosis

JAMA neurology, 2015-10, Vol.72 (10), p.1117

2015

Volltextzugriff (PDF)

Hospital admission due to infections in multiple sclerosis patients

European journal of neurology, 2013-08, Vol.20 (8), p.1153-1160

2013

Volltextzugriff (PDF)

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2009-10, Vol.374 (9700), p.1503-1511

2009

Volltextzugriff (PDF)

Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy

Journal of neurology, neurosurgery and psychiatry, 2024, Vol.95 (2), p.134-141

2024

Volltextzugriff (PDF)

Stressful life events are associated with the risk of multiple sclerosis

European journal of neurology, 2020-12, Vol.27 (12), p.2539-2548

2020

Volltextzugriff (PDF)

Multiple sclerosis and risk of attempted and completed suicide - a cohort study

European journal of neurology, 2016-08, Vol.23 (8), p.1329-1336

2016

Volltextzugriff (PDF)

Multiple sclerosis clinical course and cardiovascular disease risk - Swedish cohort study

European journal of neurology, 2014-11, Vol.21 (11), p.1353-e88

2014

Volltextzugriff (PDF)

Accurate classification of secondary progression in multiple sclerosis using a decision tree

Multiple sclerosis, 2021-07, Vol.27 (8), p.1240-1249

2021

Volltextzugriff (PDF)

Disease-modifying therapies and cost-of-illness progression among people newly diagnosed with multiple sclerosis: a national register-based cohort study covering treatment initiation with interferons, glatiramer acetate or natalizumab

BMJ open, 2023-05, Vol.13 (5), p.e067516-e067516

2023

Volltextzugriff (PDF)

Rapid discontinuation of baclofen as a treatment for spasticity among MS patients with incident and prevalent diagnoses

MULTIPLE SCLEROSIS JOURNAL, 2022, Vol.28 (Suppl. 3), p.663

2022

Volltextzugriff (PDF)

Cancer risk among patients with multiple sclerosis and their parents

Neurology, 2009-03, Vol.72 (13), p.1170-1177

2009

Volltextzugriff (PDF)

Epstein-Barr virus and multiple sclerosis: interaction with HLA

Genes and immunity, 2012-01, Vol.13 (1), p.14-20

2012

Volltextzugriff (PDF)

Topological data analysis to identify subgroups of multiple sclerosis patients with faster disease progression

MULTIPLE SCLEROSIS JOURNAL, 2018, Vol.24, p.342

2018

Volltextzugriff (PDF)

Cytomegalovirus seropositivity is negatively associated with multiple sclerosis

Multiple sclerosis, 2014-02, Vol.20 (2), p.165-173

2014

Volltextzugriff (PDF)

Different HLA-DRB1 allele distributions in distinct clinical subgroups of sarcoidosis patients

Respiratory research, 2010-02, Vol.11 (1), p.25-25, Article 25

2010

Volltextzugriff (PDF)

Socioeconomic status and multiple sclerosis outcome

Nature reviews. Neurology, 2020-04, Vol.16 (4), p.191-192

Hillert, Jan

2020

Volltextzugriff (PDF)

Sunlight is associated with decreased multiple sclerosis risk: no interaction with human leukocyte antigen-DRB115

European journal of neurology, 2012-07, Vol.19 (7), p.955-962

2012

Volltextzugriff (PDF)

Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis

Multiple sclerosis, 2016-01, Vol.22 (1), p.85-93

2016

Volltextzugriff (PDF)

Improved clinical outcomes in patients treated with natalizumab for at least 11 years - real-world data from a swedish national post-marketing surveillance study (IMSE 1)

MULTIPLE SCLEROSIS JOURNAL, 2022, Vol.28 (Suppl. 3), p.352

2022

Volltextzugriff (PDF)

Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the Swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10)

MULTIPLE SCLEROSIS JOURNAL, 2022, Vol.28 (Suppl. 3), p.638

2022

Volltextzugriff (PDF)

Clinical effectiveness and safety of dimethyl fumarate for patients treated at least 6 years in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 5" (IMSE 5)

MULTIPLE SCLEROSIS JOURNAL, 2022, Vol.28 (Suppl. 3), p.858

2022

Volltextzugriff (PDF)

MGAT5 alters the severity of multiple sclerosis

Journal of neuroimmunology, 2010-03, Vol.220 (1), p.120-124

2010

Volltextzugriff (PDF)

1 – 25 von 1.079

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.012)
Mit Volltextzugriff
(976)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Multiple Sclerosis
(97)
Journal Of Neuroimmunology
(46)
Multiple Sclerosis Journal
(28)
Neurology
(28)
The European Physical Journal. A, Hadrons And Nuclei
(27)
European Journal Of Neurology
(26)
Physics Letters. B
(17)
Physical Review Letters
(16)
Genes And Immunity
(14)
Plos One
(14)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

The Swedish MS registry - clinical support tool and scientific resource

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients

Effect of Smoking Cessation on Multiple Sclerosis Prognosis

Hospital admission due to infections in multiple sclerosis patients

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy

Stressful life events are associated with the risk of multiple sclerosis

Multiple sclerosis and risk of attempted and completed suicide - a cohort study

Multiple sclerosis clinical course and cardiovascular disease risk - Swedish cohort study

Accurate classification of secondary progression in multiple sclerosis using a decision tree

Disease-modifying therapies and cost-of-illness progression among people newly diagnosed with multiple sclerosis: a national register-based cohort study covering treatment initiation with interferons, glatiramer acetate or natalizumab

Rapid discontinuation of baclofen as a treatment for spasticity among MS patients with incident and prevalent diagnoses

Cancer risk among patients with multiple sclerosis and their parents

Epstein-Barr virus and multiple sclerosis: interaction with HLA

Topological data analysis to identify subgroups of multiple sclerosis patients with faster disease progression

Cytomegalovirus seropositivity is negatively associated with multiple sclerosis

Different HLA-DRB1 allele distributions in distinct clinical subgroups of sarcoidosis patients

Socioeconomic status and multiple sclerosis outcome

Sunlight is associated with decreased multiple sclerosis risk: no interaction with human leukocyte antigen-DRB115

Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis

Improved clinical outcomes in patients treated with natalizumab for at least 11 years - real-world data from a swedish national post-marketing surveillance study (IMSE 1)

Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the Swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10)

Clinical effectiveness and safety of dimethyl fumarate for patients treated at least 6 years in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 5" (IMSE 5)

MGAT5 alters the severity of multiple sclerosis

Suchergebnisse filtern